{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:04:34Z","timestamp":1790975074279,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Capital Clinical Diagnostic Techniques and Translational Application Projects","award":["Z211100002921059"],"award-info":[{"award-number":["Z211100002921059"]}]},{"name":"National Science and Technology Key Project on \u201cMajor Infectious Diseases such as HIV\/AIDS, Viral Hepatitis Prevention and Treatment\u201d","award":["2017ZX10302201-004, 2017ZX10202203-006"],"award-info":[{"award-number":["2017ZX10302201-004, 2017ZX10202203-006"]}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding support","doi-asserted-by":"crossref","award":["ZYLX202125"],"award-info":[{"award-number":["ZYLX202125"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Natural Science Foundation","award":["No. 7222093"],"award-info":[{"award-number":["No. 7222093"]}]},{"name":"National Key Research and Development Program of Ministry of Science and Technology","award":["2023YFC2308100"],"award-info":[{"award-number":["2023YFC2308100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-026-03086-5","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:36:44Z","timestamp":1770097004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidence and predictors of HBsAg loss following addition of pegylated interferon Alfa-2b in chronic hepatitis B patients suppressed by nucleos(t)ide analogues: a multicenter, prospective, cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Jing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanyi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liaoyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"12","key":"3086_CR1","doi-asserted-by":"publisher","first-page":"a024935","DOI":"10.1101\/cshperspect.a024935","volume":"4","author":"GS Burns","year":"2014","unstructured":"Burns GS, Thompson AJ. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med. 2014;4(12):a024935.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"3086_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"key":"3086_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","volume":"76","author":"GLH Wong","year":"2022","unstructured":"Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76:1249\u201362.","journal-title":"J Hepatol"},{"key":"3086_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/srep29605","volume":"6","author":"YC Wang","year":"2016","unstructured":"Wang YC, Yang SS, Su CW, et al. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Sci Rep. 2016;6:29605.","journal-title":"Sci Rep"},{"issue":"32","key":"3086_CR5","doi-asserted-by":"publisher","first-page":"e1341","DOI":"10.1097\/MD.0000000000001341","volume":"94","author":"IC Lee","year":"2015","unstructured":"Lee IC, Sun CK, Su CW, et al. Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B. Medicine (Baltimore). 2015;94(32):e1341.","journal-title":"Medicine (Baltimore)"},{"key":"3086_CR6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","volume":"58","author":"S Chevaliez","year":"2013","unstructured":"Chevaliez S, H\u00e9zode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013;58:676\u201383.","journal-title":"J Hepatol"},{"key":"3086_CR7","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682\u201395.","journal-title":"N Engl J Med"},{"key":"3086_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","volume":"365","author":"HL Janssen","year":"2005","unstructured":"Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123\u20139.","journal-title":"Lancet"},{"key":"3086_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","volume":"7","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013;7:88\u201397.","journal-title":"Hepatol Int"},{"issue":"11","key":"3086_CR10","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/jmv.24534","volume":"88","author":"L Boglione","year":"2016","unstructured":"Boglione L, Cariti G, Di Perri G, D'Avolio A. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. J Med Virol. 2016;88(11):1953\u20131959.","journal-title":"J Med Virol"},{"key":"3086_CR11","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3748\/wjg.v26.i13.1525","volume":"26","author":"FP Wu","year":"2020","unstructured":"Wu FP, Yang Y, Li M, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen = 1500 IU\/mL: an observational study<\/at. World J Gastroenterol. 2020;26:1525\u201339.","journal-title":"World J Gastroenterol"},{"key":"3086_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/hep.21282","volume":"44","author":"K Wursthorn","year":"2006","unstructured":"Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus Adefovir induce strong CccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44:675\u201384. [PubMed] [CrossRef] [Google Scholar].","journal-title":"Hepatology"},{"key":"3086_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","volume":"61","author":"Q Ning","year":"2014","unstructured":"Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014;61:777\u201384. https:\/\/doi.org\/10.1016\/j.jhep.2014.05.044.","journal-title":"J Hepatol"},{"key":"3086_CR14","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/hep.27586","volume":"61","author":"WP Brouwer","year":"2015","unstructured":"Brouwer WP, et al. Adding pegylated interferon to Entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study). Hepatology. 2015;61:1512\u201322. https:\/\/doi.org\/10.1002\/hep.27586.","journal-title":"Hepatology"},{"issue":"3","key":"3086_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","volume":"2","author":"M Bourli\u00e8re","year":"2017","unstructured":"Bourli\u00e8re M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grang\u00e9 JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F, ANRS HB06 PEGAN Study Group. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with hbe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol. 2017;2(3):177\u201388.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"3086_CR16","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/j.cgh.2021.04.031","volume":"20","author":"SG Lim","year":"2022","unstructured":"Lim SG, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, et al. Switching to or add-on peginterferon in patients on nucleos(t)ide analogues for chronic hepatitis B: the SWAP RCT. Clin Gastroenterol Hepatol. 2022;20(2):e228\u201350. https:\/\/doi.org\/10.1016\/j.cgh.2021.04.031.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3086_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13747-9","volume":"7","author":"J Huang","year":"2017","unstructured":"Huang J, Zhang K, Chen W, et al. Switching to PegIFN\u03b1-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs. Sci Rep. 2017;7:13383. https:\/\/doi.org\/10.1038\/s41598-017-13747-9.","journal-title":"Sci Rep"},{"key":"3086_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","volume":"6","author":"P Hu","year":"2018","unstructured":"Hu P, Shang J, Zhang W, et al. HBsAg loss with Peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol. 2018;6:25\u201334. https:\/\/doi.org\/10.14218\/JCTH.2017.00072.","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"3086_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1053\/j.gastro.2011.04.046","volume":"141","author":"TC Tseng","year":"2011","unstructured":"Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011;141(2):517\u2013525.","journal-title":"Gastroenterology"},{"key":"3086_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/jmv.21339","volume":"81","author":"F Suzuki","year":"2009","unstructured":"Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between hepatitis B virus core-related antigen and intrahepatic covalently close circular DNA in chronic hepatitis B patients. J Med Virol. 2009;81:27\u201333.","journal-title":"J Med Virol"},{"issue":"1","key":"3086_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hepr.12108","volume":"44","author":"E Tanaka","year":"2014","unstructured":"Tanaka E, Matsumoto A. Guidelines for avoiding risks resulting from discontinuation of nucleoside\/nucleotide analogs in patients with chronic hepatitis B. Hepatol Res. 2014;44(1):1\u20138.","journal-title":"Hepatol Res"},{"issue":"4","key":"3086_CR22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jhep.2022.12.017","volume":"78","author":"C Adraneda","year":"2023","unstructured":"Adraneda C, Tan YC, Yeo EJ, Kew GS, Khakpoor A, Lim SG. A critique and systematic review of the clinical utility of hepatitis B core-related antigen. J Hepatol. 2023;78(4):731\u201341.","journal-title":"J Hepatol"},{"issue":"10","key":"3086_CR23","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/hep4.1249","volume":"2","author":"J Wang","year":"2018","unstructured":"Wang J, Chen X, Wu Y, Cao Z, Wang L, Huang H, Chen X, Lu F. Serum HBV RNA is a potential predictor of hepatitis B surface antigen reversion. Hepatol Commun. 2018;2(10):1168\u201371.","journal-title":"Hepatol Commun"},{"issue":"6","key":"3086_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/jvh.13272","volume":"27","author":"MJH van Campenhout","year":"2020","unstructured":"van Campenhout MJH, van B\u00f6mmel F, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, et al. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat. 2020;27(6):610\u20139. https:\/\/doi.org\/10.1111\/jvh.13272.","journal-title":"J Viral Hepat"},{"issue":"2","key":"3086_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12072-020-10015-3","volume":"14","author":"M Zhang","year":"2020","unstructured":"Zhang M, Li G, Shang J, Pan C, Zhang M, Yin Z, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int. 2020;14(2):212\u201324.","journal-title":"Hepatol Int"},{"issue":"5","key":"3086_CR26","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1097\/HEP.0000000000000413","volume":"78","author":"MG Ghany","year":"2023","unstructured":"Ghany MG, King WC, Hinerman AS, Lok AS, Lisker-Melman M, Chung RT, Terrault N, Janssen HLA, Khalili M, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Use of HBV RNA and to predict change in serological status and disease activity in CHB. Hepatology. 2023;78(5):1542\u201357. Epub 2023 Apr 20. PMID: 37074026.","journal-title":"Hepatology"},{"key":"3086_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.14218\/JCTH.2016.00019","volume":"5","author":"J Hou","year":"2017","unstructured":"Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, et al. Chinese society of hepatology, Chinese medical association; Chinese society of infectious diseases, Chinese medical association. Guideline of prevention and treatment for chronic hepatitis B (2015 update). J Clin Transl Hepatol. 2017;5:297\u2013318.","journal-title":"J Clin Transl Hepatol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03086-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03086-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03086-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:08:13Z","timestamp":1772582893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03086-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3086"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03086-5","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the principles of the Declaration of Helsinki. Approval for the experimental therapy and study protocol was obtained from the local ethics committee at each participating center. Written informed consent was obtained from all subjects prior to their participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was waived because all data presented in this study are de-identified and do not contain any individual or identifiable personal information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}